ronopterin
Phase 1- Indications
- Traumatic brain injury, Glioblastoma multiforme, Diabetic retinopathy, Metastatic brain tumor
Company intelligence / Profile preview
veriNOS Pharmaceuticals
Würzburg, Bavaria, Germanydnb.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
veriNOS’ lead product Ronopterin, a selective iNOS inhibitor, has shown repeated signs of biochemical and clinical neuroprotection in patients with traumatic brain injury. The company holds orphan drug designation in the EU for TBI with 10 years market exclusivity and has filed new IP extending protection until 2042. Proof-of-concept studies are ongoing or planned for additional indications such as peritumoral brain edema and retinal edema
- Therapeutic areas
- OphthalmologyOncologyNeurology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Not specified; supported by institutional and individual investors
Beyond the preview
Go deeper on veriNOS Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on veriNOS Pharmaceuticals.